COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #240 of 260
1/23 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Cifuentes et al., Medicina ClĂ­nica (English Edition), doi:10.1016/j.medcle.2020.10.012 (Peer Reviewed)
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine
Source   PDF   Share   Tweet
Retrospective 3,817 chronic HCQ patients showing 4.4% COVID-19 positive rate, 1.3% severe. There is no comparison with a control group. Authors note that there was a 3.6% incidence among 2,032,863 patients in one of the regions (Castilla La Mancha), however they provide no information on this group - it is expected that the mostly systemic autoimmune disease patients in the treatment group are older on average. Additonally, other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [1].

Cifuentes et al., 1/23/2021, peer-reviewed, 18 authors.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.